Sun Joon Moon

Dr. Sun Joon Moon


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2021 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
SMSun Joon Moon
Sun Joon Moon
IJInha Jung
Inha Jung
Cheol-Young ParkCheol-Young Park
Cheol-Young Park
Since Banting and Best isolated insulin in the 1920s, dramatic progress has been made in the treatment of type 1 diabetes mellitus (T1DM). However, dose titration and timely injection to maintain optimal glycemic control are often challenging for T1DM patients and their families because they require frequent blood glucose checks. In recent years, technological advances in insulin pumps and continuous glucose monitoring systems have created paradigm shifts in T1DM care that are being extended to develop artificial pancreas systems (APSs). Numerous studies that demonstrate the superiority of glycemic control offered by APSs over those offered by conventional treatment are still being published, and rapid commercialization and use in actual practice have already begun. Given this rapid development, keeping up with the latest knowledge in an organized way is confusing for both patients and medical staff. Herein, we explore the history, clinical evidence, and current state of APSs, focusing on various development groups and the commercialization status. We also discuss APS development in groups outside the usual T1DM patients and the administration of adjunct agents, such as amylin analogues, in APSs.

23 September 2022 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
SMSun Joon Moon
Sun Joon Moon
KKKyung‐Soo Kim
Kyung‐Soo Kim
WLWoo Je Lee
Woo Je Lee
MLMi Yeon Lee
Mi Yeon Lee
RVRobert Vigersky
Robert Vigersky
Cheol-Young ParkCheol-Young Park
Cheol-Young Park

6 October 2024 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
DKDavid C. Klonoff
David C. Klonoff
Guido FreckmannGuido Freckmann
Guido Freckmann
SPStefan Pleus
Stefan Pleus
BKBoris P. Kovatchev
Boris P. Kovatchev
DKDavid Kerr
David Kerr
MKMichael A. Kohn
Michael A. Kohn
Introduction: An error grid compares measured versus reference glucose concentrations to assign clinical risk values to observed errors. Widely used error grids for blood glucose monitors (BGMs) have limited value because they do not also reflect clinical accuracy of continuous glucose monitors (CGMs). Methods: Diabetes Technology Society (DTS) convened 89 international experts in glucose monitoring to (1) smooth the borders of the Surveillance Error Grid (SEG) zones and create a user-friendly tool—the DTS Error Grid; (2) define five risk zones of clinical point accuracy (A-E) to be identical for BGMs and CGMs; (3) determine a relationship between DTS Error Grid percent in Zone A and mean absolute relative difference (MARD) from analyzing 22 BGM and nine CGM accuracy studies; and (4) create trend risk categories (1-5) for CGM trend accuracy. Results: The DTS Error Grid for point accuracy contains five risk zones (A-E) with straight-line borders that can be applied to both BGM and CGM accuracy data. In a data set combining point accuracy data from 18 BGMs, 2.6% of total data pairs equally moved from Zones A to B and vice versa (SEG compared with DTS Error Grid). For every 1% increase in percent data in Zone A, the MARD decreased by approximately 0.33%. We also created a DTS Trend Accuracy Matrix with five trend risk categories (1-5) for CGM-reported trend indicators compared with reference trends calculated from reference glucose. Conclusion: The DTS Error Grid combines contemporary clinician input regarding clinical point accuracy for BGMs and CGMs. The DTS Trend Accuracy Matrix assesses accuracy of CGM trend indicators.

31 October 2020 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
SMSun Joon Moon
Sun Joon Moon
EREun-Jung Rhee
Eun-Jung Rhee
JJJin-Hyung Jung
Jin-Hyung Jung
KHKyung-Do Han
Kyung-Do Han
SKSung-Rae Kim
Sung-Rae Kim
KYKun-Ho Yoon
Kun-Ho Yoon
Background: Inconsistent results have been observed regarding the independent effect of diabetes on the severity of coronavirus disease 2019 (COVID-19). We conducted a nationwide population-based cohort study to evaluate the relationship between diabetes and COVID-19 severity in South Korea. Methods: Patients with laboratory-confirmed COVID-19 aged >= 30 years were enrolled and medical claims data were obtained from the Korean Health Insurance Review and Assessment Service. Hospitalization, oxygen treatment, ventilator application, and mortality were assessed as severity outcomes. Multivariate logistic regression analyses were performed after adjusting for age, sex, and comorbidities. Results: Of 5,307 COVID-19 patients, the mean age was 56.0 +/- 14.4 years, 2,043 (38.5%) were male, and 770 (14.5%) had diabetes. The number of patients who were hospitalized, who received oxygen, who required ventilator support, and who died was 4,986 (94.0%), 884 (16.7%), 121 (2.3%), and 211 (4.0%), respectively. The proportion of patients with diabetes in the abovementioned outcome groups was 14.7%, 28.1%, 41.3%, 44.6%, showing an increasing trend according to outcome severity. In multivariate analyses, diabetes was associated with worse outcomes, with an adjusted odds ratio (aOR) of 1.349 (95% confidence interval [CI], 1.099 to 1.656; P=0.004) for oxygen treatment, an aOR of 1.930 (95% CI, 1.276 to 2.915; P< 0.001) for ventilator use, and an aOR of 2.659 (95% CI, 1.896 to 3.729; P< 0.001) for mortality. Conclusion: Diabetes was associated with worse clinical outcomes in Korean patients with COVID-19, independent of other comorbidities. Therefore, patients with diabetes and COVID-19 should be treated with caution.

2 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HJHan Na Jang
Han Na Jang
SMSun Joon Moon
Sun Joon Moon
KJKyeong Cheon Jung
Kyeong Cheon Jung
SKSang Wan Kim
Sang Wan Kim
HKHyeyoon Kim
Hyeyoon Kim
JKJung Hee Kim
Jung Hee Kim
Adrenal cortical carcinoma (ACC) is an extremely rare disease with a variable prognosis. Current prognostic markers have limitations in identifying patients with a poor prognosis. Herein, we aimed to investigate the prognostic protein biomarkers of ACC using mass-spectrometry-based proteomics. We performed the liquid chromatography–tandem mass spectrometry (LC–MS/MS) using formalin-fixed paraffin-embedded (FFPE) tissues of 45 adrenal tumors. Then, we selected 117 differentially expressed proteins (DEPs) among tumors with different stages using the machine learning algorithm. Next, we conducted a survival analysis to assess whether the levels of DEPs were related to survival. Among 117 DEPs, HNRNPA1, C8A, CHMP6, LTBP4, SPR, NCEH1, MRPS23, POLDIP2, and WBSCR16 were significantly correlated with the survival of ACC. In age- and stage-adjusted Cox proportional hazard regression models, only HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 expression remained significant. These five proteins were also validated in TCGA data as the prognostic biomarkers. In this study, we found that HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 were protein biomarkers for predicting the prognosis of ACC.

22 November 2024 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
AAAlessandra T. Ayers
Alessandra T. Ayers
CHCindy N. Ho
Cindy N. Ho
DKDavid Kerr
David Kerr
SCSimon Lebech Cichosz
Simon Lebech Cichosz
NMNestoras Mathioudakis
Nestoras Mathioudakis
DKDavid C. Klonoff
David C. Klonoff
Artificial intelligence (AI) is increasingly being used to diagnose complications of diabetes. Artificial intelligence is technology that enables computers and machines to simulate human intelligence and solve complicated problems. In this article, we address current and likely future applications for AI to be applied to diabetes and its complications, including pharmacoadherence to therapy, diagnosis of hypoglycemia, diabetic eye disease, diabetic kidney diseases, diabetic neuropathy, diabetic foot ulcers, and heart failure in diabetes. Artificial intelligence is advantageous because it can handle large and complex datasets from a variety of sources. With each additional type of data incorporated into a clinical picture of a patient, the calculation becomes increasingly complex and specific. Artificial intelligence is the foundation of emerging medical technologies; it will power the future of diagnosing diabetes complications.